Myocardial hypermetabolism and fibrosis on 2-[18F]FDG PET/CT correlated with sudden cardiac death risk scores in hypertrophic cardiomyopathy (rho=0.38, p=0.036 and rho=0.38, p=0.039, respectively).
Does myocardial resting perfusion and metabolism imaging using [13N]-NH3 and 2-[18F]FDG PET/CT correlate with sudden cardiac death risk scores in patients with non-obstructive hypertrophic cardiomyopathy?
Myocardial hypermetabolism and fibrosis assessed by PET/CT correlate with sudden cardiac death risk scores in non-obstructive HCM, suggesting a potential role for metabolic imaging in risk stratification.
Absolute Event Rate: 0% vs 0%
Risk stratification for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) remains challenging. Enhanced imaging techniques could improve prognostic accuracy. This study investigates myocardial resting perfusion and metabolism using 13N-NH3 and 2-18FFDG PET/CT and their correlation with HCM SCD risk scores. Thirty non-obstructive HCM patients (mean age 54 years, 57% male) with a mean SCD risk score of 3.7 ± 2.5% were evaluated. Myocardial 2-18FFDG metabolism and rest 13N-NH3 perfusion PET/CT were analyzed. Hypermetabolism (2-18FFDG uptake with normal perfusion) occurred in 53% of cases (mean extension 11.8 ± 17.2%), while fibrosis (reduced perfusion without 2-18FFDG uptake) averaged 10.3 ± 10.2%. Mean rest myocardial blood flow (MBF) was 0.75 ± 0.21 ml/min/g, increasing with hypermetabolism extension (0.83 ± 0.32 ml/min/g for ≥ 20%, p = 0.019) but decreasing with SCD scores ≥ 6% (0.58 ± 0.05 ml/min/g, p = 0.034). Hypermetabolism correlated moderately with SCD risk scores (rho = 0.38, p = 0.036), with hypermetabolism peaking at intermediate risk (23.5 ± 27.1%) before declining. Fibrosis extension consistently increased with SCD risk (rho = 0.38, p = 0.039). In conclusion, our findings identify important correlations between myocardial hypermetabolism and fibrosis and SCD risk in HCM. Hypermetabolism peaks in intermediate-risk patients, reflecting earlier disease stages, while fibrosis increases with higher SCD risk, signaling disease progression and structural damage.
Marques‐Alves et al. (Fri,) reported a other. Myocardial hypermetabolism and fibrosis on 2-[18F]FDG PET/CT correlated with sudden cardiac death risk scores in hypertrophic cardiomyopathy (rho=0.38, p=0.036 and rho=0.38, p=0.039, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: